110 related articles for article (PubMed ID: 19682883)
1. Prognostic value of the 6min walk test in bronchiolitis obliterans syndrome.
Nathan SD; Shlobin OA; Reese E; Ahmad S; Fregoso M; Athale C; Barnett SD
Respir Med; 2009 Dec; 103(12):1816-21. PubMed ID: 19682883
[TBL] [Abstract][Full Text] [Related]
2. Post-transplant baseline FEV1 and the development of bronchiolitis obliterans syndrome: an important confounder?
Burton CM; Iversen M; Mortensen J; Carlsen J; Andersen CB; Milman N; Scheike T
J Heart Lung Transplant; 2007 Nov; 26(11):1127-34. PubMed ID: 18022078
[TBL] [Abstract][Full Text] [Related]
3. Long-term health-related quality of life and walking capacity of lung recipients with and without bronchiolitis obliterans syndrome.
Gerbase MW; Soccal PM; Spiliopoulos A; Nicod LP; Rochat T
J Heart Lung Transplant; 2008 Aug; 27(8):898-904. PubMed ID: 18656804
[TBL] [Abstract][Full Text] [Related]
4. Bronchiolitis obliterans syndrome: incidence, natural history, prognosis, and risk factors.
Heng D; Sharples LD; McNeil K; Stewart S; Wreghitt T; Wallwork J
J Heart Lung Transplant; 1998 Dec; 17(12):1255-63. PubMed ID: 9883768
[TBL] [Abstract][Full Text] [Related]
5. Acute cellular rejection is a risk factor for bronchiolitis obliterans syndrome independent of post-transplant baseline FEV1.
Burton CM; Iversen M; Carlsen J; Mortensen J; Andersen CB; Steinbrüchel D; Scheike T
J Heart Lung Transplant; 2009 Sep; 28(9):888-93. PubMed ID: 19716040
[TBL] [Abstract][Full Text] [Related]
6. The value of D-dimer in lung transplant recipients with bronchiolitis obliterans syndrome.
Shitrit D; Amital A; Fox B; Kramer MR
Respir Med; 2008 Feb; 102(2):205-9. PubMed ID: 17976973
[TBL] [Abstract][Full Text] [Related]
7. Improved lung allograft function after fundoplication in patients with gastroesophageal reflux disease undergoing lung transplantation.
Davis RD; Lau CL; Eubanks S; Messier RH; Hadjiliadis D; Steele MP; Palmer SM
J Thorac Cardiovasc Surg; 2003 Mar; 125(3):533-42. PubMed ID: 12658195
[TBL] [Abstract][Full Text] [Related]
8. The impact of cytolytic therapy on bronchiolitis obliterans syndrome.
Date H; Lynch JP; Sundaresan S; Patterson GA; Trulock EP
J Heart Lung Transplant; 1998 Sep; 17(9):869-75. PubMed ID: 9773858
[TBL] [Abstract][Full Text] [Related]
9. Comparison of bronchiolitis obliterans syndrome to other forms of chronic lung allograft dysfunction after lung transplantation.
Woodrow JP; Shlobin OA; Barnett SD; Burton N; Nathan SD
J Heart Lung Transplant; 2010 Oct; 29(10):1159-64. PubMed ID: 20580267
[TBL] [Abstract][Full Text] [Related]
10. Restrictive allograft syndrome (RAS): a novel form of chronic lung allograft dysfunction.
Sato M; Waddell TK; Wagnetz U; Roberts HC; Hwang DM; Haroon A; Wagnetz D; Chaparro C; Singer LG; Hutcheon MA; Keshavjee S
J Heart Lung Transplant; 2011 Jul; 30(7):735-42. PubMed ID: 21419659
[TBL] [Abstract][Full Text] [Related]
11. Seasonal onset of bronchiolitis obliterans syndrome in lung transplant recipients.
Hohlfeld J; Niedermeyer J; Hamm H; Schäfers HJ; Wagner TO; Fabel H
J Heart Lung Transplant; 1996 Sep; 15(9):888-94. PubMed ID: 8889984
[TBL] [Abstract][Full Text] [Related]
12. Course of FEV(1) after onset of bronchiolitis obliterans syndrome in lung transplant recipients.
Lama VN; Murray S; Lonigro RJ; Toews GB; Chang A; Lau C; Flint A; Chan KM; Martinez FJ
Am J Respir Crit Care Med; 2007 Jun; 175(11):1192-8. PubMed ID: 17347496
[TBL] [Abstract][Full Text] [Related]
13. Methotrexate can halt the progression of bronchiolitis obliterans syndrome in lung transplant recipients.
Dusmet M; Maurer J; Winton T; Kesten S
J Heart Lung Transplant; 1996 Sep; 15(9):948-54. PubMed ID: 8889991
[TBL] [Abstract][Full Text] [Related]
14. Long-term azithromycin for bronchiolitis obliterans syndrome after lung transplantation.
Gottlieb J; Szangolies J; Koehnlein T; Golpon H; Simon A; Welte T
Transplantation; 2008 Jan; 85(1):36-41. PubMed ID: 18192909
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of bronchiolitis obliterans syndrome stage 0-p in single-lung transplant recipients.
Lama VN; Murray S; Mumford JA; Flaherty KR; Chang A; Toews GB; Peters-Golden M; Martinez FJ
Am J Respir Crit Care Med; 2005 Aug; 172(3):379-83. PubMed ID: 15894603
[TBL] [Abstract][Full Text] [Related]
16. Impact of Forced Expiratory Volume in 1 Second (FEV1) and 6-Minute Walking Distance at 3, 6, and 12 Months and Annually on Survival and Occurrence of Bronchiolitis Obliterans Syndrome (BOS) After Lung Transplantation.
Fakhro M; Ingemansson R; Algotsson L; Lindstedt S
Ann Transplant; 2017 Sep; 22():532-540. PubMed ID: 28871078
[TBL] [Abstract][Full Text] [Related]
17. Bronchial hyperresponsiveness and the bronchiolitis obliterans syndrome after lung transplantation.
Reid DW; Walters EH; Johns DP; Ward C; Burns GP; Liakakos P; Williams TJ; Snell GI
J Heart Lung Transplant; 2005 Apr; 24(4):489-92. PubMed ID: 15797754
[TBL] [Abstract][Full Text] [Related]
18. Effect of adherence to home spirometry on bronchiolitis obliterans and graft survival after lung transplantation.
Kugler C; Fuehner T; Dierich M; DeWall C; Haverich A; Simon A; Welte T; Gottlieb J
Transplantation; 2009 Jul; 88(1):129-34. PubMed ID: 19584692
[TBL] [Abstract][Full Text] [Related]
19. Prevalence and outcome of bronchiolitis obliterans syndrome after lung transplantation. Washington University Lung Transplant Group.
Sundaresan S; Trulock EP; Mohanakumar T; Cooper JD; Patterson GA
Ann Thorac Surg; 1995 Nov; 60(5):1341-6; discussion 1346-7. PubMed ID: 8526624
[TBL] [Abstract][Full Text] [Related]
20. Actuarial survival of heart-lung and bilateral sequential lung transplant recipients with obliterative bronchiolitis.
Valentine VG; Robbins RC; Berry GJ; Patel HR; Reichenspurner H; Reitz BA; Theodore J
J Heart Lung Transplant; 1996 Apr; 15(4):371-83. PubMed ID: 8732596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
